James Moy to Treatment Outcome
This is a "connection" page, showing publications James Moy has written about Treatment Outcome.
Connection Strength
0.137
-
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga?) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study. J Clin Immunol. 2017 Aug; 37(6):603-612.
Score: 0.078
-
Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases. Immunotherapy. 2018 10; 10(14):1193-1202.
Score: 0.021
-
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex? 10% Versus Gammaplex? 5% in Subjects with Primary Immunodeficiency. J Clin Immunol. 2017 Apr; 37(3):301-310.
Score: 0.019
-
Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016 12; 138(6):1608-1618.e12.
Score: 0.019